NAV
Also available at a lower cost as an Admiral™ Shares mutual fund.
Management style
Asset class
CUSIP | 921908307 |
---|---|
Management style | Active |
Asset class | Domestic Stock - Sector-Specific |
Category | Health |
Inception date | 05/23/1984 |
Fund Number | 0052 |
YTD returns
For more than 25 years, this actively managed fund has offered investors low-cost exposure to domestic and foreign companies involved in various aspects of the health care industry, such as pharmaceutical firms, medical supply companies, and research firms. The fund tends to be more geographically diverse and exhibit lower turnover than other health care funds. Still, one risk to note is the fund’s narrow scope, investing solely within the health care sector. Returns may vary widely from year to year, so this fund should be considered complementary to a diversified portfolio with a long-term time horizon.
Wellington Management Company LLP
as of 12/31/2024
Recent returns
Average annual
Month-end | 3-Month total | YTD | 1-yr | 3-yr | 5-yr | 10-yr | Since inception 05/23/1984 | |
---|---|---|---|---|---|---|---|---|
VGHCX | -6.67% | -12.31% | -1.59% | -1.59% | 0.88% | 5.73% | 7.26% | 14.84% |
-5.90% | -11.41% | 1.07% | 1.07% | -0.58% | 5.81% | 7.01% | 10.36% |
as of 12/31/2024
Year | 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr | Year-end | |
---|---|---|---|---|---|---|
2024 | 5.07% | 3.05% | 3.64% | -12.31% | -1.59% | 1.07% |
2023 | -0.59% | 4.25% | -4.60% | 6.64% | 5.43% | 3.58% |
2022 | -3.09% | -5.57% | -3.30% | 11.82% | -1.05% | -6.14% |
2021 | -0.29% | 10.70% | -1.23% | 4.84% | 14.30% | 17.50% |
2020 | -10.98% | 16.16% | 4.11% | 4.61% | 12.62% | 14.87% |
2019 | 7.91% | -0.98% | -1.53% | 16.84% | 22.93% | 22.67% |
2018 | 0.21% | 0.52% | 13.07% | -11.18% | 1.15% | 1.71% |
2017 | 10.58% | 6.54% | 0.97% | 0.55% | 19.61% | 20.14% |
2016 | -8.84% | 5.42% | 0.71% | -5.97% | -8.99% | -6.83% |
2015 | 9.64% | 3.80% | -8.90% | 8.65% | 12.65% | 6.33% |
2014 | 8.84% | 5.17% | 3.90% | 8.06% | 28.52% | 18.13% |
as of 12/31/2024
Year | Capital return by NAV | Income return by NAV | Total return by NAV | |
---|---|---|---|---|
2024 | -2.47% | 0.89% | -1.59% | 1.07% |
2023 | 4.58% | 0.85% | 5.43% | 3.58% |
2022 | -1.82% | 0.76% | -1.05% | -6.14% |
2021 | 13.36% | 0.94% | 14.30% | 17.50% |
2020 | 11.67% | 0.95% | 12.62% | 14.87% |
2019 | 21.58% | 1.35% | 22.93% | 22.67% |
2018 | 0.01% | 1.15% | 1.15% | 1.71% |
2017 | 18.46% | 1.15% | 19.61% | 20.14% |
2016 | -9.85% | 0.86% | -8.99% | -6.83% |
2015 | 11.39% | 1.26% | 12.65% | 6.33% |
2014 | 27.34% | 1.17% | 28.52% | 18.13% |
2013 | 41.43% | 1.76% | 43.19% | 35.76% |
2012 | 12.98% | 2.13% | 15.11% | 17.77% |
2011 | 9.55% | 1.90% | 11.45% | 8.89% |
2010 | 4.48% | 1.68% | 6.16% | 5.44% |
2009 | 19.23% | 1.74% | 20.96% | 19.70% |
as of 12/31/2024
1-yr | 3-yr | 5-yr | 10-yr | Since inception 05/23/1984 | |
---|---|---|---|---|---|
VGHCX | -1.59% | 2.67% | 32.15% | 101.52% | 27461.64% |
1.07% | -1.74% | 32.62% | 96.94% | — |
VGHCX
0.35%
Average expense ratio of similar funds2
1.01%
Purchase fee
None
Fund family redemption fee
None
None
The performance data shown represent past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate so that investors' shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data cited.
Performance data do not reflect the deduction of the $25 annual account service fee that may be applied to certain accounts. If this fee was included, performance would be lower.
NAV
NAV change
52-week High
52-week Low
52-week Difference
Name | Date | NAV |
---|---|---|
VGHCX | 01/17/2025 | $182.55 |
This chart can’t be displayed on mobile devices. For the best viewing experience, visit this page from your desktop or laptop.
as of 12/31/2024
Fundamental | VGHCX | |
---|---|---|
Number of stocks | 84 | 219 |
Median market cap | $131.6 B | $150.3 B |
Earnings growth rate | 7.0% | 7.2% |
Short-term reserves | 1.5% | — |
P/E ratio | 26.2x | 29.8x |
P/B ratio | 4.2x | 4.2x |
Turnover rate (Fiscal Year-end 01/31/2024) | 16.3% | — |
Return on equity | 18.2% | 20.0% |
Foreign holdings | 29.3% | — |
Fund total net assets as of 12/31/2024 | $40.5 B | — |
Share class total net assets | $6.2 B | — |
as of 12/31/2024
Weighted equity exposures exclude any temporary cash investments and equity index futures. Some short-term fixed income securities are classified as cash and are excluded from the weighted bond exposures.
as of 09/30/2024
Ticker | Holdings | Shares | Market value |
---|---|---|---|
LLY | Eli Lilly & Co. | 4,709,105 | $4,171,984,484 |
UNH | UnitedHealth Group Inc. | 6,347,754 | $3,711,404,809 |
AZN | AstraZeneca plc | 17,636,106 | $2,747,465,549 |
MRK | Merck & Co. Inc. | 19,273,919 | $2,188,746,242 |
NOVO B | Novo Nordisk A/S Class B | 16,015,062 | $1,899,570,848 |
NOVN | Novartis AG | 14,193,639 | $1,634,288,129 |
DHR | Danaher Corp. | 4,931,523 | $1,371,062,024 |
PFE | Pfizer Inc. | 41,635,060 | $1,204,918,636 |
ELV | Anthem Inc. | 2,238,250 | $1,163,890,000 |
BSX | Boston Scientific Corp. | 13,757,254 | $1,152,857,885 |
Ticker | Holdings | Shares | Market value |
---|---|---|---|
LLY | Eli Lilly & Co. | 4,709,105 | $4,171,984,484 |
UNH | UnitedHealth Group Inc. | 6,347,754 | $3,711,404,809 |
AZN | AstraZeneca plc | 17,636,106 | $2,747,465,549 |
MRK | Merck & Co. Inc. | 19,273,919 | $2,188,746,242 |
NOVO B | Novo Nordisk A/S Class B | 16,015,062 | $1,899,570,848 |
NOVN | Novartis AG | 14,193,639 | $1,634,288,129 |
DHR | Danaher Corp. | 4,931,523 | $1,371,062,024 |
PFE | Pfizer Inc. | 41,635,060 | $1,204,918,636 |
ELV | Anthem Inc. | 2,238,250 | $1,163,890,000 |
BSX | Boston Scientific Corp. | 13,757,254 | $1,152,857,885 |
Ticker | Holdings | Shares | Market value |
---|---|---|---|
LLY | Eli Lilly & Co. | 4,709,105 | $4,171,984,484 |
UNH | UnitedHealth Group Inc. | 6,347,754 | $3,711,404,809 |
AZN | AstraZeneca plc | 17,636,106 | $2,747,465,549 |
MRK | Merck & Co. Inc. | 19,273,919 | $2,188,746,242 |
NOVO B | Novo Nordisk A/S Class B | 16,015,062 | $1,899,570,848 |
NOVN | Novartis AG | 14,193,639 | $1,634,288,129 |
DHR | Danaher Corp. | 4,931,523 | $1,371,062,024 |
PFE | Pfizer Inc. | 41,635,060 | $1,204,918,636 |
ELV | Anthem Inc. | 2,238,250 | $1,163,890,000 |
BSX | Boston Scientific Corp. | 13,757,254 | $1,152,857,885 |
Realized gain
% of NAV
Unrealized gains of NAV
% of NAV
Fiscal year end
Distribution schedule
A fund's capital gains and losses can reveal the tax implications of holding a particular fund in a taxable account. This is true of both realized and unrealized capital gains and losses.
Learn about realized and unrealized gains and lossesA fund's capital gains and losses can reveal the tax implications of holding a particular fund in a taxable account. This is true of both realized and unrealized capital gains and losses.
Learn about realized and unrealized gains and lossesInvestment Manager Biography
Performance & fees
Most recent data available. © 2023 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; (3) does not constitute investment advice offered by Morningstar; and (4) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
R-squared and beta are calculated from trailing 36-month fund returns relative to the associated benchmark.
Portfolio composition
Sector categories are based on the Global Industry Classification Standard (“GICS”), except for the “Other” category (if applicable), which includes securities that have not been provided a GICS classification as of the effective reporting period.
© 2023 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Vanguard average mutual fund expense ratio: 0.09%. Industry average mutual fund expense ratio: 0.50%. All averages are asset-weighted. Industry average excludes Vanguard. Sources: Vanguard and Morningstar, Inc., as of December 31, 2023.
Total returns: Short-term total return information is provided only as a service. Historical performance—particularly short-term performance—is no guarantee of future returns. Price, yield, and return on an actual investment will fluctuate, and you may have a gain or loss when you sell. Average annual returns include changes in price and reinvestments of dividends and capital gains. Since-inception returns for less than 1 year and year-to-date returns aren't annualized. Index performance is provided as a benchmark but isn't illustrative of any particular investment. You can't invest in an index.
Standardized returns: To see quarterly fee-adjusted returns, refer to the Price & Performance details.
Expense ratios: Expense ratios are displayed on Overview. For investments that are less than 1 fiscal year old, expense ratios are estimated.
Risk: All investing is subject to risk, including the possible loss of the money you invest. Funds that concentrate on a relatively narrow market sector face the risk of higher share-price volatility. Investments in stocks or bonds issued by non-U.S. companies are subject to risks including country/regional risk and currency risk.
An investment in the fund could lose money over short or long periods of time. You should expect the fund’s share price and total return to fluctuate within a wide range. The fund is subject to the following risks, which could affect the fund’s performance: